Why Is VIRIDIAN THERAPEUTIC (VRDN) Stock Up Today?

Viridian Therapeutics shares surged 15.53% to close at $29.06, driven by third-quarter results that exceeded expectations and a significant price target increase from Goldman Sachs. The stock’s sharp gain reflects strong initial sales for its lead product, Lumvoa, and a clear timeline for its next major regulatory filing.

What Happened

The primary catalyst was the company’s Q3 2026 earnings report, which showed GAAP EPS of -$0.81, beating the consensus estimate by $0.21. Revenue of $24.7 million also topped forecasts, marking a substantial year-over-year increase. Management highlighted that the first full quarter of Lumvoa sales beat expectations as patient starts accelerated.

Following the release, Goldman Sachs raised its price target for VRDN to $53 from $40. The company also provided a specific roadmap for its pipeline, signaling that the Biologics License Application for Elegrobart is expected in Q1 2027. Additionally, management stated that Lumvoa launch targets broad coverage within six to nine months. A Form 8-K filed on November 4, 2026, disclosed these preliminary results and financial statements.

What The Data Shows

The stock printed a fresh 52-week high on November 4, 2026, alongside 16 fresh 52-week lows recorded on the same date. The current price of $29.06 sits within the 52-week range of $13.18 to $34.29. Fundamentals show a market capitalization of $2.9 billion with a beta of 1.07. The company remains unprofitable with a trailing twelve-month EPS of -$3.46, though revenue growth is recorded at 23,220.3% over the same period.

In the 90 days prior to the move, there were no insider buys and one sale totaling $348,000. General Counsel Jennifer Tousignant sold shares on August 19, 2026. Over the eight sessions leading up to the earnings release, the stock was relatively flat, moving only 0.1% from $23.93 to $23.90.

What To Watch

Investors will monitor the progress of the Elegrobart BLA filing scheduled for Q1 2027 and the expansion of Lumvoa coverage. With seven stories from five sources in the last 36 hours, coverage breadth remains high as the market digests the updated valuation metrics.